[로이슈 편도욱 기자] Celltrion’s COVID-19 antibody treatment ‘Rekkorona (development name: CT-P59, ingredient name: Regdanvimab)’ received ‘official approval’ from the European Commission (EC) on the 12th local time has obtained
On the 11th (Europe local time), Lekkorana received an ‘approval recommendation’ opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA). ‘product license’ has been obtained. With this, Rekkona secured the status of the first antibody drug in Korea to obtain official product approval in Europe.
A Celltrion official said, “It is very unusual for the EC to issue an official product approval within one day of the EMA’s recommendation for approval of Reckrona. “We will do our best to help many COVID-19 patients benefit from the proven safety and effectiveness of Rekkona, and through this, contribute to the end of the global COVID-19 crisis.”
Reporter Pyun Do-wook Roisshu toy1000@hanmail.net
.
